In this issue:
Prostate cancer screening with MRI
Quality of life with docetaxel or abiraterone plus ADT
Health-related QOL in mHSPC
Abiraterone for mHSPC and visceral metastases
ADT use and duration with definitive radiotherapy
Local ablative image-guided radiotherapy for oligometastatic prostate cancer
Optimising follow-up after suspicious MRI and negative biopsy
Utility of subclassifying positive surgical margins at radical prostatectomy
Active surveillance in Gleason GG 2 prostate cancer
Long-term adverse pathology and distant metastasis and prostate cancer mortality
Please login below to download this issue (PDF)